Advance in microRNA as a potential biomarker for early detection of pancreatic cancer

被引：33

作者：

Huang J. ^{[1
]}

Liu J. ^{[1
]}

Chen-Xiao K. ^{[2
]}

Zhang X. ^{[2
]}

Paul Lee W.N. ^{[2
]}

Go V.L.W. ^{[2
]}

Xiao G.G. ^{[1
,2
,3
]}

机构：

[1] School of Pharmaceutical Science and Technology, Dalian University of Technology, Dalian

[2] Harbor-University of California Los Angeles Research and Education Institute, UCLA, School of Medicine, Torrance, 90502, CA

[3] Genomics and Functional Proteomics Laboratories, Creighton University Medical Center, Omaha, 68131, NE

来源：

Biomarker Research | / 4卷 / 1期

关键词：

Biomarker; Cancer stem cells; Early detection; MicroRNAs; Pancreatic cancer; Signal transduction;

D O I：

10.1186/s40364-016-0074-3

中图分类号：

学科分类号：

摘要：

Pancreatic cancer is characterized as a disease with low survival and high mortality because of no effective diagnostic and therapeutic strategies available in clinic. Conventional clinical diagnostic methods including serum markers and radiological imaging (CT, MRI, EUS, etc.) often fail to detect precancerous or early stage lesions. Development of effective biomarkers is unmet for reduction of mortality of pancreatic cancer. MicroRNAs (miRNAs) are a group of small non-protein-coding RNAs playing roles in regulation of cell physiology including tumorigenesis, apoptotic escape, proliferation, invasion, epithelial-mesenchymal transition (EMT), metastasis and chemoresistance. Various altered signaling pathways involving in molecular pathogenesis of pancreatic cancer are mediated by miRNAs as a role of either oncogenes or tumor suppressors. Among biomarkers developed including protein, metabolites, DNA, RNA, epigenetic mutation, miRNAs are superior because of its unique chemical property. Recent study suggests that miRNAs may be promising biomarkers used for early detection of pancreatic cancer. This review will update the progression made in early detection of pancreatic cancer. © 2016 The Author(s).

引用

共 23 条

[1]

Li A., Yu J., Kim H., Wolfgang C.L., Canto M.I., Hruban R.H., Et al., MicroRNA array analysis finds elevated serum MIR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls, Clin Cancer Res, 19, 13, pp. 3600-3610, (2013)

[2]

Chitkara D., Mittal A., Mahato R.I., MiRNAs in pancreatic cancer: Therapeutic potential, delivery challenges and strategies, Adv Drug Deliv Rev, 81, pp. 34-52, (2015)

[3]

Rachagani S., Macha M.A., Heimann N., Seshacharyulu P., Haridas D., Chugh S., Et al., Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer, Adv Drug Deliv Rev, 81, pp. 16-33, (2015)

[4]

Munding J.B., Adai A.T., Maghnouj A., Urbanik A., Zollner H., Liffers S.T., Et al., Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma, Int J Cancer, 131, 2, pp. E86-E95, (2012)

[5]

Oberg K., Modlin I.M., Herder W.D., Pavel M., Klimstra D., Consensus on biomarkers for neuroendocrine tumour disease, Lancet Oncol, 16, pp. e435-e446, (2015)

[6]

Miura F., Takada T., Amano H., Yoshida M., Furui S., Takeshita K., Diagnosis of pancreatic cancer, HPB, 8, 5, pp. 337-342, (2006)

[7]

Duffy M.J., Sturgeon C., Lamerz R., Haglund C., Holubec V.L., Klapdor R., Et al., Tumor markers in pancreatic cancer: A European Group on Tumor Markers (EGTM) status report, Ann Oncol, 21, 3, pp. 441-447, (2010)

[8]

Karius T., Schnekenburger M., Dicato M., Diederich M., MicroRNAs in cancer management and their modulation by dietary agents, Biochem Pharmacol, 83, 12, pp. 1591-1601, (2012)

[9]

Brunetti O., Russo A., Scarpa A., Santini D., Reni M., Bittoni A., Et al., MicroRNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets?, Oncotarget, 6, 27, pp. 23323-23341, (2015)

[10]

Khan S., Ansarullah D.K., Jaggi M., Chauhan S.C., Targeting microRNAs in pancreatic cancer: Microplayers in the big game, Cancer Res, 73, 22, pp. 6541-6547, (2013)

← 1 2 3 →